Kanaph Therapeutics Inc.

Kanaph Therapeutics Inc. is a biotechnology company engaged in drug discovery and early-stage clinical trials in South Korea and the United States. Its therapeutic platform includes bispecific antibodies, Fc-fusions, and small molecules. The company is developing KNP-101, KNP-301, KNP-502, KNP-503, KNP-504, and KNP-701 for various cancers and eye diseases. Founded in 2019, it is headquartered in Seoul, South Korea.